While the US president is touting his initiative as a populist attack on drug companies, analysts question whether prices will be affordable for many people.
Published February 6, 2026
US President Donald Trump has launched a new website aimed at lowering the cost of prescription drugs, which have long been marked by high prices in the US compared to similar products around the world.
At a White House event on Thursday, President Trump announced the launch of TrumpRx, a new website that allows consumers to buy drugs directly from drug companies at discounted prices.
Recommended stories
list of 3 itemsend of list
“People will save a lot of money and be healthier,” Trump said, noting that some of the world’s largest drug companies have agreed to lower prices under a “most-favoured-nation” agreement in exchange for avoiding U.S. tariffs.
The website will offer discounts on more than 40 popular medicines, the White House said.
Users can search for the drug they want on the site, print a coupon, and present it at a pharmacy to purchase it at a discounted price.
The Trump administration pitched the initiative as a populist attack on powerful pharmaceutical companies amid growing dissatisfaction with economic conditions.
A group of 16 drug companies has agreed to discount deals to offer lower prices on certain drugs to U.S. consumers through government programs such as Medicaid and TrumpRx.
The TrumpRx site, which promises “the world’s lowest prices for prescription drugs,” features more than 40 drugs, including weight loss drugs like Ozempic and Wigovy, and calls the effort “the most impactful prescription price reset in our nation’s history.”
“Thanks to President Trump, the days of price gouging for Big Pharma are over,” the website says.
But analysts question whether the initiative will substantively address U.S. drug prices or shake up the pharmaceutical industry.
“There are real questions about the value of this insurance to the insured,” Juliette Cubansky, deputy director of Medicare policy at the health policy organization KFF, told news agency Reuters.
“In some cases, out-of-pocket costs that are still relatively unaffordable for many people may be considered,” Cubansky said.
TrumpRx is representative of the US president’s individualistic policy-making style, seeking to terminate individual deals to advance his own priorities rather than using traditional regulatory and legislative tools.
An earlier analysis by KFF said details of most-favored-nation agreements with companies “remain secret, meaning that little is publicly known about what exactly was agreed.”
Pharmaceutical companies remain a powerful force in US politics, with watchdog group Open Secret reporting that drug makers spent a record $187 million on lobbying in 2025.
